SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020 financial results after the market close on Thursday, March 26, 2020. Management will host a conference call and webcast to review the results and provide an operational update.
Conference Call and Webcast Details:
Thursday, March 26 @ 5:00 p.m. EDT / 2:00 p.m. PDT
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 1668357
Webcast: http://investors.atyrpharma.com/events-and-webcastsAbout aTyraTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. For more information, please visit http://www.atyrpharma.com.
Bay Street News